Possible PDA Side Effects
Medical-review status: A licensed medical reviewer has not yet been assigned to this page. Until one is, the page is published as an editorial draft and is not presented as medically reviewed. See our medical review policy.
Quick answer
The side-effect profile of Pentadeca Arginate is essentially unknown because it has not been formally studied in humans. U.S. authorities warn that unapproved and compounded peptides can carry risks such as immune reactions, impurities, and mislabeling.
No systematic human safety data exist for PDA; concerns come from the unapproved-peptide context. (Only small, preliminary, or low-quality human data.)
Why the honest answer is "largely unknown"
No direct evidence identifiedA drug’s side-effect profile is established through controlled human studies and post-market surveillance. Neither exists for Pentadeca Arginate, so no one can accurately list its side effects.
Documented concerns about unapproved peptides
Limited human evidenceThe FDA has identified potential risks for compounded BPC-157, including immunogenicity for certain routes of administration, peptide-related impurities and characterization challenges, and limited human safety data.[1],[2]
The Department of Defense’s Operation Supplement Safety describes BPC-157 as an unapproved drug that is not a dietary ingredient and warns about "research chemical" products of uncertain content.[3]
What to do with this uncertainty
Talk to a licensed clinician
Because safety is not established, discuss any interest in peptides with a licensed U.S. clinician, and never stop or replace prescribed treatment. This page does not provide dosing or injection instructions.
Frequently asked questions
Is PDA free of side effects?
No product can be assumed "side-effect free." PDA has not been studied in humans, so its side effects are unknown, and unapproved peptides carry documented risks.
References
3 peer-reviewed journal sources and 3 additional authoritative references. Every reference supports a specific statement above.
- [1] U.S. Food and Drug Administration (2025). Certain bulk drug substances for use in compounding that may present significant safety risks. FDA.gov, Regulatory information (compounding safety). View source Government / regulatory
- [2] U.S. Food and Drug Administration (2025). Bulk drug substances used in compounding under section 503A of the FD&C Act. FDA.gov, Regulatory information (compounding). View source Government / regulatory
- [3] Operation Supplement Safety (U.S. Department of Defense) (2024). BPC-157: a prohibited peptide and an unapproved drug found in health and wellness products. OPSS.org (DoD), U.S. government consumer-safety advisory. View source Government / regulatory
- [4] Gwyer D, Wragg NM, Wilson SL (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377(2):153–159. View source Peer-reviewed journal
- [5] Vasireddi N, Hahamyan H, Salata MJ, et al. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal (SAGE), Systematic review. View source Peer-reviewed journal
- [6] Current Reviews in Musculoskeletal Medicine (2025). Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Current Reviews in Musculoskeletal Medicine, Narrative review. View source Peer-reviewed journal